It can be extrapolated that POCU1b may act as an anti-obesity agent by inhibiting pancreatic lipase and mediating cAMP-dependent PDE inhibition, leading to reduced perilipin and ADRP levels. Here, ALDH7A1 is linked to obesity due to melanocortin 4 receptor deficiency.